Skip to main content
. 2019 Nov 12;3(21):3406–3418. doi: 10.1182/bloodadvances.2019000564

Table 1.

Clinical profile of patients with MDS with thrombocytopenia

Feature Isolated thrombocytopenia (n = 191) Bicytopenia (n = 389) Pancytopenia (n = 530) P
Age at diagnosis, y 56 (37-68) 57 (38.5-66) 53 (38-63) .056
Sex .137
 Female 95 (49.7) 162 (41.6) 247 (46.6)
 Male 96 (50.3) 227 (58.4) 283 (53.4)
Cytopenias
 Hb, g/dL 117 (108-131) 94 (69-113) 71 (58-84) .000
 ANC, ×109/L 3.0 (2.2-4.7) 1.9 (1.2-3.2) 0.9 (0.5-1.3) .000
 Platelets, × 109/L 46 (31-67) 46 (25-70) 35 (18-63) .000
 Severe thrombocytopenia 19 (9.9) 64 (16.5) 152 (28.7) .000
 Moderate thrombocytopenia 87 (45.5) 144 (37.0) 180 (34.0)
Bone marrow blasts, % 2.5 (1.0-5.0) 4.0 (1.8-8.5) 4.0 (1.2-10.5) .000
WHO classification .000
 MDS-SLD 26 (13.6) 59 (15.2) 82 (15.5)
 MDS-MLD 9 (4.7) 25 (6.4) 23 (4.3)
 MDS-RS 2 (1.0) 5 (1.3) 6 (1.1)
 5q- 0 0 1 (0.2)
 MDS-EB-1 44 (23.0) 108 (27.8) 103 (19.4)
 MDS-EB-2 19 (9.9) 84 (21.6) 149 (28.1)
 MDS-U 91 (47.6) 108 (27.8) 166 (31.3)
Cytogenetic risk
 Very good 3 (1.6) 8 (2.1) 7 (1.3) .037
 Good 110 (57.6) 227 (58.4) 291 (54.9)
 Intermediate 63 (33.0) 103 (26.5) 135 (25.5)
 Poor 8 (4.2) 19 (4.9) 38 (7.2)
 Very poor 7 (3.7) 32 (8.2) 59 (11.1)
MK 13 (6.8) 61 (15.7) 77 (14.5) .014
IPSS-R
 Very low 25 (13.1) 13 (3.3) 0 (0.0) .000
 Low 85 (44.5) 79 (20.3) 49 (9.2)
 Intermediate 32 (16.8) 144 (37.0) 170 (32.1)
 High 34 (17.8) 91 (23.4) 138 (26.0)
 Very high 15 (7.9) 62 (15.9) 173 (32.6)
AML evolution 24 (12.6) 61 (15.7) 121 (22.8) .002

Data are n (%) or median (interquartile range).

5q-, MDS with isolated del(5q); ANC, absolute neutrophil count; Hb, hemoglobin; IPSS-R, Revised International Prognostic Scoring System; MDS-EB, MDS with excess blasts; MDS-MLD, MDS with multilineage dysplasia; MDS-RS, MDS with ring sideroblasts; MDS-SLD, MDS with single-lineage dysplasia; MDS-U, MDS-unclassifiable; MK, monosomal karyotype; WBC, white blood cell.